GPCR Profile
Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company specializing in the development and delivery of novel oral therapeutics aimed at treating chronic diseases with significant unmet medical needs. The company’s primary focus is on leveraging advanced pharmacological research to create innovative treatments, particularly for conditions such as type 2 diabetes mellitus and obesity. Its leading product candidate, GSBR-1290, is an oral small molecule agonist targeting the glucagon-like-peptide-1 receptor (GLP-1R), a well-established G-protein-coupled receptor (GPCR) known for its role in glucose regulation and weight management.
In addition to GSBR-1290, Structure Therapeutics is advancing a diverse pipeline of oral small molecule therapeutics targeting various GPCRs. Notably, the company is developing ANPA-0073, a biased agonist targeting the apelin receptor, which is implicated in diseases such as idiopathic pulmonary fibrosis (IPF) and pulmonary arterial hypertension. Another key candidate is LTSE-2578, an investigational oral small molecule designed to act as a lysophosphatidic acid 1 receptor antagonist, with potential applications in treating IPF. These therapeutic candidates represent the company's commitment to addressing a broad spectrum of serious and chronic conditions.
Structure Therapeutics employs a strategic approach to drug development, combining cutting-edge science with innovative drug delivery systems to maximize therapeutic efficacy. The company’s research and development efforts are driven by a deep understanding of GPCR biology and its implications in various disease states. By focusing on high-impact therapeutic areas, Structure Therapeutics aims to deliver transformative solutions that can significantly improve patient outcomes and quality of life.
Originally founded as ShouTi Inc. in 2016, Structure Therapeutics Inc. has since evolved to establish itself as a prominent player in the biopharmaceutical industry. Headquartered in South San Francisco, California, the company continues to expand its research capabilities and therapeutic portfolio, positioning itself at the forefront of advancements in chronic disease treatment and management.
|
